Project Grant R01DA066471
- The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University $718,124 on September 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate chronic cannabinoid vapor exposure effects on the brain and behavior. The research examines whether repeated exposure to vaporized delta-9-tetrahydrocannabinol (THC) causes lasting behavioral and neurological alterations in adult male and female rats, including disrupted neural connectivity, white matter...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $708,190 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to conduct double-blind, placebo-controlled human laboratory studies examining the pharmacokinetic and pharmacodynamic effects of varying tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios in cannabis edibles. Research Aim 1 will evaluate how different THC:CBD ratios—including 1:0, 1:1, 1:5, 1:10, 1:30, and 0:1—affect THC...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $194,271 under Project Grant R21DA064845 on May 1, 2026, for exploratory research on rodent models of cannabis drug discrimination and self-administration to support medication development for cannabis use disorder. The recipient will develop and optimize rodent models using vaporized cannabis extract to establish reliable drug discrimination and self-administration procedures. Aim 1 applies drug discrimination...
- The National Institute on Drug Abuse awarded Carnegie Mellon University $191,250 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate THC exposure and inhibitory circuit plasticity in the neocortex. The research examines acute and long-term effects of tetrahydrocannabinol (THC), the main psychoactive component of cannabis, on neocortical interneurons expressing the highest levels of cannabinoid receptors in the mammalian brain. The project will...
- The National Institute on Drug Abuse awarded The Leland Stanford Junior University $160,840 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate TRPV1-mediated vascular and neuronal dysregulation induced by natural and synthetic cannabinoids. The research examines differential impacts of natural cannabinoids (cannabidiol, delta-9-tetrahydrocannabinol) and synthetic cannabinoids (cannabinol, hexahydrocannabinol) on vascular and neuronal function, with...
- The National Institute on Drug Abuse awarded Washington State University $420,750 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological substrates of cannabis-seeking behavior through preclinical research models. The funded research combines fiber photometry and wireless recording techniques to examine how dynamic neural activity and dopamine release in corticostriatal circuits—specifically the medial prefrontal cortex and nucleus...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $211,680 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026. The recipient will conduct mixed-methods research characterizing hemp-derived alternative cannabinoid product use in natural settings. The project comprises two national, decentralized studies: an online survey and a six-month naturalistic ecological momentary assessment study. Research will assess alternative...
- The National Institute on Drug Abuse awarded the Research Foundation For Mental Hygiene, Inc. (operating through its New York State Psychiatric Institute division) $195,804 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year research project examining how cannabis influences nicotine use among young and emerging adults (ages 18–35) who use electronic nicotine delivery systems. The study integrates human laboratory methods with...
- The National Institute on Drug Abuse awarded Auburn University $173,128 on November 29, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support training and experimental research on the neurobiological mechanisms underlying cannabis use disorder. The project, titled "Experimental Manipulation of the Emotional Salience of Cannabis Use-Related Information," will provide training in transcranial magnetic stimulation (TMS) methodology, magnetic resonance imaging...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $385,638 to The Regents of the University of Colorado (University of Colorado-Denver) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, with a completion date of August 31, 2028. This research award funds a three-year neurobehavioral investigation titled "Cannabinoid Tolerance Across Neurodevelopment: Disruption of Value-Driven Behavior and Prevention Through...
The National Institute on Drug Abuse awarded The Johns Hopkins University $631,094 on August 1, 2026, for research evaluating the neurocognitive, psychomimetic, and abuse-related effects of emerging psychoactive cannabinoids under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year project (August 1, 2026 through June 30, 2031) examining vaporized delta-8 tetrahydrocannabinol (D8-THC) and hexahydrocannabinol (HHC)—novel cannabinoids marketed as legal alternatives to delta-9 THC. Aim 1 evaluates neurocognitive and psychomimetic effects by testing adverse effects on sustained attention, motor speed, anxiety-like behavior, and sensorimotor gating using rodent models including the psychomotor vigilance task, acoustic startle response, and prepulse inhibition test. Aim 2 evaluates conditioned rewarding and reinforcing effects relative to D9-THC through conditioned place preference and vapor self-administration experiments, and characterizes tolerance and withdrawal potential. The research also characterizes the pharmacokinetics and metabolite activity of D8-THC and HHC to determine their mechanisms of action beyond CB1 receptor agonism. Work is performed at Johns Hopkins in Baltimore, Maryland.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $631.1k | 7/23/26 |